ULTRAGENYX PHARMACEUTICAL INC. - COMMON STOCK

Ultragenyx and GeneTx Provide Program Update on GTX-102 for Angelman Syndrome Including Promising Interim Data from Phase 1/2 Study

18 Jul 2022 15:00:00 By Nasdaq GlobeNewswire

Ultragenyx Announces Sale of a Portion of Future North American Royalties on Crysvita® (burosumab) for $500 Million to OMERS Capital Markets

14 Jul 2022 07:30:00 By Nasdaq GlobeNewswire

Ultragenyx to Present at Goldman Sachs Global Healthcare Conference

10 Jun 2022 07:00:00 By Nasdaq GlobeNewswire

Ultragenyx to Present at Jefferies Global Healthcare Conference

01 Jun 2022 15:01:00 By Nasdaq GlobeNewswire

Ultragenyx Announces Positive Longer-term Durability Data from Two Phase 1/2 Gene Therapy Studies at American Society of Gene & Cell Therapy (ASGCT) 2022 Annual Meeting

19 May 2022 07:00:01 By Nasdaq GlobeNewswire

Ultragenyx Acquires Global Rights to AAV Gene Therapy ABO-102 for Sanfilippo Syndrome Type A (MPS IIIA) from Abeona Therapeutics

17 May 2022 07:00:02 By Nasdaq GlobeNewswire

Ultragenyx Announces Upcoming Data Presentations at American Society of Gene & Cell Therapy (ASGCT) 2022 Annual Meeting

09 May 2022 07:00:01 By Nasdaq GlobeNewswire

Ultragenyx Reports First Quarter 2022 Financial Results and Corporate Update

05 May 2022 15:05:02 By Nasdaq GlobeNewswire

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

03 May 2022 16:00:00 By Nasdaq GlobeNewswire

Ultragenyx to Participate at BofA Securities 2022 Healthcare Conference

03 May 2022 15:05:01 By Nasdaq GlobeNewswire

Ultragenyx to Host Conference Call for First Quarter 2022 Financial Results and Corporate Update

27 Apr 2022 15:01:00 By Nasdaq GlobeNewswire

Ultragenyx Issues Inaugural Environmental, Social and Governance (ESG) Report

25 Apr 2022 12:18:09 By Nasdaq GlobeNewswire

Ultragenyx Appoints Amrit Ray, M.D., M.B.A. to Board of Directors

22 Apr 2022 07:00:00 By Nasdaq GlobeNewswire

Ultragenyx Announces First Patient Dosed in Pivotal Phase 2/3 Clinical Study of Setrusumab (UX143) for the Treatment of Osteogenesis Imperfecta

20 Apr 2022 07:00:01 By Nasdaq GlobeNewswire

Ultragenyx to Participate in the Cowen Health Care Conference

02 Mar 2022 15:01:00 By Nasdaq GlobeNewswire

Ultragenyx Reports Fourth Quarter and Full Year 2021 Financial Results and Corporate Update

10 Feb 2022 15:05:01 By Nasdaq GlobeNewswire

Ultragenyx to Host Conference Call for Fourth Quarter and Full-Year 2021 Financial Results and Corporate Update

03 Feb 2022 15:01:00 By Nasdaq GlobeNewswire

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

02 Feb 2022 15:05:00 By Nasdaq GlobeNewswire

Ultragenyx Reports Preliminary 2021 Revenue and 2022 Revenue Guidance for Crysvita® in Ultragenyx Territories* And Dojolvi® Globally; Provides Pipeline Updates and 2022 Milestones

10 Jan 2022 07:00:02 By Nasdaq GlobeNewswire

Ultragenyx to Present at H.C. Wainwright BioConnect Healthcare Conference

06 Jan 2022 15:01:00 By Nasdaq GlobeNewswire